{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:07:13Z","timestamp":1791450433411,"version":"4.3.3"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.esmoop.2021.100064","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T02:35:34Z","timestamp":1615430134000},"page":"100064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study"],"prefix":"10.1016","volume":"6","author":[{"given":"M.","family":"Guida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ramondetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Chiaron Sileni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Antonini Cappellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Queirolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ridolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cocorocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Festino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Merelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Occelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Brugnara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Minisini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tommasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"De Summa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2021.100064_bib1","first-page":"480","article-title":"Identifying and managing the adverse effects of immune check-point blockade","volume":"10","author":"Winer","year":"2018","journal-title":"J\u00a0Thorac"},{"issue":"17","key":"10.1016\/j.esmoop.2021.100064_bib2","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1001\/jama.2017.14155","article-title":"Targeting immune check-points in cancer therapy","volume":"318","author":"Topalian","year":"2017","journal-title":"J\u00a0Am Med Assoc"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100064_bib3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune check-point inhibitor therapy: American Society of Clinical Oncology Clinical Practice guideline summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100064_bib4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune check-point blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100064_bib5","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour and class-specific patterns of immune-related adverse events of immune check-point inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100064_bib6","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1046\/j.1523-1747.1999.00805.x","article-title":"Accumulation of identical T cells in melanoma and vitiligo-like leukoderma","volume":"113","author":"Becker","year":"1999","journal-title":"J\u00a0Invest Dermatol"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100064_bib7","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/archderm.1987.01660320095019","article-title":"Prognostic significance of hypopigmentation in malignant melanoma","volume":"123","author":"Bystryn","year":"1987","journal-title":"Arch Dermatol"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100064_bib8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon","volume":"354","author":"Gogas","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100064_bib9","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1038\/sj.jid.5700545","article-title":"Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma","volume":"126","author":"Boasberg","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100064_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdp325","article-title":"Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study","volume":"21","author":"Quaglino","year":"2010","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100064_bib11","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100064_bib12","first-page":"906","article-title":"Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma","volume":"5","author":"Quach","year":"2019","journal-title":"J\u00a0Am Med Assoc"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100064_bib13","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100064_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100064_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100064_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J\u00a0Dermatol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100064_bib17","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100064_bib18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/CMR.0000000000000518","article-title":"Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma","volume":"29","author":"Hwang","year":"2019","journal-title":"Melanoma Res"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100064_bib19","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1610-0387.2008.06755.x","article-title":"Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features","volume":"6","author":"Hartmann","year":"2008","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100064_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100064_bib21","doi-asserted-by":"crossref","first-page":"684","DOI":"10.18632\/oncotarget.323","article-title":"New perspectives on the role of vitiligo in immune responses to melanoma","volume":"2","author":"Byrne","year":"2011","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100064_bib22","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100064_bib23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100064_bib24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100064_bib25","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/jdv.16311","article-title":"Cutaneous adverse events: a predictor of tumour response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients","volume":"34","author":"Bottlaender","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100064_bib26","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/1346-8138.15309","article-title":"Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: a single institutional retrospective study","volume":"47","author":"Nakano","year":"2020","journal-title":"J\u00a0Dermatol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100064_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40264-019-00875-6","article-title":"Occurrences and outcomes of immune checkpoint inhibitors-induced vitiligo in cancer patients: a retrospective cohort study","volume":"43","author":"Babai","year":"2020","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100064_bib28","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100064_bib29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.molonc.2008.01.002","article-title":"EORTC Melanoma group. Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas","volume":"1","author":"Kannengiesser","year":"2008","journal-title":"Mol Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100064_bib30","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favourable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1-2","key":"10.1016\/j.esmoop.2021.100064_bib31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1615\/CritRevOncog.2016017150","article-title":"Immune responses to BRAF-targeted therapy in melanoma: is targeted therapy immunotherapy?","volume":"21","author":"Kelley","year":"2016","journal-title":"Crit Rev Oncog"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100064_bib32","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/annonc\/mdx059","article-title":"Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab","volume":"29","author":"Ferrucci","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100064_bib33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","article-title":"Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab","volume":"6","author":"Capone","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100064_bib34","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdt027","article-title":"Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival","volume":"24","author":"Delyon","year":"2013","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100064_bib35","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3390\/cancers11101559","article-title":"The management of oligoprogression in the landscape of new therapies for metastatic melanoma","volume":"11","author":"Guida","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2021.100064_bib36","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1146\/annurev.immunol.021908.132557","article-title":"Blood monocytes: development, heterogeneity, and relationship with dendritic cells","volume":"27","author":"Auffray","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.esmoop.2021.100064_bib37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-3-030-34025-4_9","article-title":"Monocytes and macrophages in cancer: unsuspected roles","volume":"1219","author":"Gouveia-Fernandes","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.esmoop.2021.100064_bib38","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.coi.2018.03.009","article-title":"Plasticity of myelopid-derived suppressor cells in cancer","volume":"51","author":"Tcyganov","year":"2018","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100064_bib39","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1159\/000445644","article-title":"Prognostic significance of monocytes and monocytic myeloid-derived suppressor cells in diffuse large B-cell lymphoma treated with R-CHOP","volume":"39","author":"Wu","year":"2016","journal-title":"Cell Physiol Biochem"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292100020X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292100020X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:24:21Z","timestamp":1761855861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292100020X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S205970292100020X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100064","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100064"}}